Ionis Pharmaceuticals Inc
IONS
NASDAQ
Biotechnology
$57.24
USD
+1.37 (+2.45%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $9.28B
Volume 1.3M
Revenue
$874.09M
TTM
-7.4%
YoY
Gross Margin
98%
TTM
-0.7%
YoY
Net Income
$-565.17M
TTM
-110.7%
YoY
Operating Cash Flow
$-496.43M
TTM
-115.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 452.0 | 156.7 | 203.3 | 246.1 | 267.9 |
YoY Growth | +100.7% | +17.1% | -10.3% | +87.0% | -40.7% |
Cost of Revenue | 4.2 | 2.3 | 8.0 | 3.0 | 2.7 |
Gross Profit | 447.9 | 154.4 | 195.4 | 243.1 | 265.2 |
Selling, General & Administrative | 90.6 | 96.8 | 130.2 | 150.4 | 150.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 308.1 | 314.6 | 409.8 | 360.5 | 367.5 |
Operating Income | 139.8 | -160.2 | -214.5 | -117.4 | -102.3 |
EBITDA | 142.7 | -157.3 | -213.0 | -113.5 | -98.2 |
Other Income / Expense | 6.5 | 30.3 | -15.5 | 22.1 | 11.0 |
Total Other Income / Expense | -16.3 | 31.8 | -13.5 | 25.1 | -11.1 |
Income Before Income Taxes | 123.5 | -128.4 | -227.9 | -92.3 | -113.4 |
Income Taxes | -0.0 | 0.2 | 1.5 | 0.2 | 1.3 |
Net Income | 123.6 | -128.6 | -229.4 | -92.5 | -114.6 |
Consolidated Net Income / Loss | 123.6 | -128.6 | -229.4 | -92.5 | -114.6 |
Net Income Attributable to Common Shareholders | 123.6 | -128.6 | -229.4 | -92.5 | -114.6 |
Basic EPS | $0.78 | -$0.80 | -$1.41 | -$0.56 | -$0.69 |
Diluted EPS | $0.70 | -$0.80 | -$1.65 | -$0.56 | -$0.69 |
Basic Shares Outstanding | 159.1M | 159.8M | 162.4M | 164.9M | 165.4M |
Diluted Shares Outstanding | 182.3M | 159.8M | 139.2M | 164.9M | 165.4M |